Video Series

Dr Coney discusses the variability of frequency dosing with anti-VEGF therapy in patients with wet AMD and DME, and Dr Sheth expands on Ang-2 and its contribution to the development of vascular instability in wet AMD.

Roy Beveridge, MD, and Brian Koffman, MD, explore how the Bruton tyrosine kinase inhibitors (BTKi) fit into value-based care models for oncology and the patient support offered to aid patients in gaining access to BTKis.

Brian Koffman, MD, and Roy Beveridge, MD, discuss the financial burdens of Bruton tyrosine kinase inhibitor therapy and considerations for oral therapy vs infusion therapy.

Amy McMichael, MD, provides an overview of the Psorcast app and how it can benefit treatment adherence for patients.

Bruce Sherman, MD, FCCP, FACOEM, and Maria Lopes, MD, MS, discuss how organizations can address disparities in care for psoriasis.

Experts discuss the effect and safety of lomitapide and evinacumab in treating patients with HoFH.

Drs Brinton and Michos highlight LDL-C apheresis in the treatment landscape for homozygous familial hypercholesterolemia [HoFH].

Dr Sheth discusses his insights on anti-VEGF therapy that he has noticed in the treatment of wet AMD over the last decade, and Caesar Luo, MD, FASRS, FACS shares his insight on new treatment options and their impact on patient access and cost considerations.

Dr Coney and Veeral Sheth, MD, MBA, FACS, FASRS, discuss treatment selection, treatment goals, and unmet needs for patients diagnosed with wet AMD and DME.

Callie Coombs, MD, reviews how patients develop resistance to Bruton Tyrosine Kinase inhibitor (BTKi) therapy and how BTKi resistance is managed.

Roy Beveridge, MD, discusses how payers and health systems are managing Bruton tyrosine kinase inhibitors and how they are chosen for formulary and pathway coverage.

Maria Lopes, MD, MS, reviews some challenges surrounding access to care, patient education, and financial burdens associated with psoriasis across skin phototypes.

Amy McMichael, MD, discusses ways to ensure patients of all races and ethnicities are experiencing the same level of quality face-to-face interactions with their providers.

The treatment landscape of HoFH is discussed by Eliot Brinton, MD.

Key opinion leaders discuss drivers in health care utilization for patients diagnosed with HoFH.

In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment.

Joseph Coney, MD, FASRS, FACS, discusses the difference between population groups in age-related macular degeneration (AMD) and diabetic macular edema (DME)

Jim Kenney, RPh, MBA, opens a discussion surrounding wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

In the final discussion, expert panelists navigate treatment sequencing in MM treatment strategies.

Dr Nadeem provides community and clinical strategies to treat patients with MM.

Callie Coombs, MD, discusses how pirtobrutinib (LOXO-305), a Bruton tyrosine kinase inhibitor (BTKi) being investigated in the BRUIN trial, might impact the BTKi landscape.

Brian Koffman, MD, reviews how Bruton tyrosine kinase inhibitors are addressing unmet needs in chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and what unmet needs remain.

Maria Lopes, MD, MS, reviews how to educate providers on the risks and burdens of psoriasis and how to improve early diagnosis and treatment for all skin phototypes and ethnicities.

Bruce Sherman, MD, FCCP, FACOEM, underlines how to support patients financially to afford therapies and maintain adherence.

Dr Brinton provides an overview of guideline-directed therapies in HoFH.

Seth Baum, MD, and Erin Michos, MD, MHS, discuss pediatric diagnosis of homozygous FH.

In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS.

Dr De Castro explores considerations surrounding cost in treatment of PNH.

Dr Lipe shares disparities between academic and community practice settings for patients with MM.

Highlighted are updates in NCCN guidelines for frontline MM treatment strategies.